Managing bipolar depression
Abstract
What should the clinician do when confronted with a patient who has depressive symptoms? Seek the proper diagnosis. Question the patient about depressive symptoms over a two-week course that interferes with social and/or occupational functioning. Determine if there is any history of mania or hypomania. Information from a significant other is extremely useful as well. Coexisting diagnoses, such as substance abuse, posttraumatic stress disorder, or medical conditions, must be ruled in or out. It is critical to include a suicide risk assessment in the evaluation. Lithium is still the gold standard for bipolar patients with its suicide preventative effects. Lamotrigine appears to have the advantage of efficacy against bipolar depression without high risk for inducing mania. Experts recommend that a mood stabilizer be used in combination with antidepressants. The tricyclic antidepressants and the monoamine oxidase inhibitors appear to have the highest risk for mania and are best avoided. Atypical antipsychotic medications are best utilized for psychotic symptoms and as adjuncts to existing antidepressants. Cognitive behavioral therapy may complement pharmacotherapy.
Similar articles
-
Using antipsychotic agents in older patients.J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. J Clin Psychiatry. 2004. PMID: 14994733 Review.
-
[Antipsychotics in bipolar disorders].Encephale. 2004 Sep-Oct;30(5):417-24. doi: 10.1016/s0013-7006(04)95456-5. Encephale. 2004. PMID: 15627046 Review. French.
-
Bipolar II disorder : epidemiology, diagnosis and management.CNS Drugs. 2007;21(9):727-40. doi: 10.2165/00023210-200721090-00003. CNS Drugs. 2007. PMID: 17696573 Review.
-
Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers.Am J Psychiatry. 2006 Feb;163(2):232-9. doi: 10.1176/appi.ajp.163.2.232. Am J Psychiatry. 2006. PMID: 16449476 Clinical Trial.
-
ECNP consensus meeting. Bipolar depression. Nice, March 2007.Eur Neuropsychopharmacol. 2008 Jul;18(7):535-49. doi: 10.1016/j.euroneuro.2008.03.003. Epub 2008 May 23. Eur Neuropsychopharmacol. 2008. PMID: 18501566 Review.
Cited by
-
Increased PKC activity and altered GSK3β/NMDAR function drive behavior cycling in HINT1-deficient mice: bipolarity or opposing forces.Sci Rep. 2017 Feb 27;7:43468. doi: 10.1038/srep43468. Sci Rep. 2017. PMID: 28240305 Free PMC article.
References
-
- National Institute of Mental Health. Bipolar disorder research at the national institute of health. 2000. www.nimh.nih.gov/pub;icat/bipolarresfact.cfm.
-
- Bowden CL. Managing bipolar depression. J Clin Psychiatry. 2004;65(suppl 10):3–4. - PubMed
-
- White SH. Mechanism of action of newer anticonvulsants. J Clin Psychiatry. 2003;64(suppl 8):5–8. - PubMed
-
- Sadock BJ, Sadock VA. Mood disorders. In: Sadock VA, editor. Kaplan & Sadock's Synopsis of Psychiatry, Ninth Edition. Philadelphia: Lippincott Williams & Wilkins; 2003. pp. 534–90.
-
- Hirschfeld RM. Bipolar spectrum disorder: Improving its recognition and diagnosis. J Clin Psychiatry. 2001;62(14):5–9. - PubMed
LinkOut - more resources
Full Text Sources